Arch Biopartners Inc.
ARCH.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 100.00% | 163.43% | -92.06% | -87.40% | -106.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.00% | 163.43% | -92.06% | -87.40% | -106.46% |
| Cost of Revenue | -0.41% | -42.25% | -84.19% | -94.77% | -53.41% |
| Gross Profit | 11.41% | 64.64% | 75.48% | 104.30% | -392.50% |
| SG&A Expenses | 50.76% | 48.54% | 47.49% | -35.22% | -36.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.65% | 4.76% | -51.17% | -75.62% | -44.26% |
| Operating Income | -24.58% | 11.82% | 24.63% | 68.32% | -0.77% |
| Income Before Tax | -21.44% | 12.78% | 28.07% | 63.49% | 11.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.44% | 12.78% | 28.07% | 63.49% | 11.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.44% | 12.78% | 28.07% | 63.49% | 11.92% |
| EBIT | -24.58% | 11.82% | 24.63% | 68.32% | -0.77% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -15.15% | 17.60% | 32.06% | 65.30% | 12.58% |
| Normalized Basic EPS | -15.06% | 16.90% | 31.42% | 64.83% | 12.17% |
| EPS Diluted | -15.15% | 17.60% | 32.06% | 65.30% | 12.58% |
| Normalized Diluted EPS | -15.06% | 16.90% | 31.42% | 64.83% | 12.17% |
| Average Basic Shares Outstanding | 3.57% | 4.22% | 4.76% | 5.34% | 2.68% |
| Average Diluted Shares Outstanding | 3.57% | 4.22% | 4.76% | 5.34% | 2.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |